Beneficial Effect of Thymelaea hirsuta on Pancreatic Islet Degeneration, Renal Fibrosis, and Liver Damages as Demonstrated in Streptozotocin-Induced Diabetic Rat

Objective In Morocco, Thymelaea hirsuta (T. hirsuta) (Thymelaeacea) is a medicinal plant widely used to treat and prevent diabetes. The present study aimed to evaluate the medium-term antidiabetic effect of aqueous extract (AqTh) and ethyl acetate fraction (EaTh) of Th and to investigate their putative protective effect on pancreatic islet degeneration, diabetic nephropathy, and liver damages in streptozotocin (STZ)-diabetic rats. Methods Experimental diabetes in rats was induced by a single intraperitoneal injection of 50 mg/kg of STZ. During the treatment period (4 weeks), 200 mg/kg AqTh and 50 mg/kg EaTh were orally administrated daily to STZ-diabetic rats. A group of parameters including fasting blood glucose, biochemical parameters, and intestinal α-glucosidase inhibition were studied. Furthermore, histological study of the pancreas, kidney, liver, and aorta was also realized. Results At the end of the treatment, both AqTh and EaTh had normalized fasting blood glucose to 1.08 and 1.25 g/l, respectively. AqTh has also reduced urinary creatinine and HbAc1. The EaTh showed inhibitory activity against intestinal α-glucosidase, whereas AqTh did not have this inhibitory effect. Furthermore, pancreas hematoxylin and eosin staining showed that AqTh or EaTh prevents pancreatic islet cell degeneration. As the same kidney, Masson's trichrome staining has shown a significant prevention of renal fibrosis in AqTh- or EaTh-treated diabetic rats. On the other hand, liver hematoxylin and eosin staining showed that AqTh and EaTh prevent liver damage. Conclusion We conclude that medium-term administration of AqTh and EaTh exerts significant antihyperglycemic effect in STZ-diabetic rats possibly through intestinal α-glucosidase inhibition and protection against pancreatic islet cell damage. Moreover, AqTh and EaTh treatment prevent nephropathy and liver complications in STZ-diabetic rats.


Introduction
Diabetes mellitus is the most common endocrine disease. e incidence of this disease is increasing at an alarming rate (4-5%) [1]. Untreated or noncontrolled, noninsulin-dependent type 2 diabetes (DM2) can cause several complications such as cardiovascular diseases and diabetic nephropathy, and it may lead to insulin-dependent type 1 diabetes (DM1). e diabetic nephropathy is one of the important complications of diabetes, and it is the main reason for the increased number of patients with end-stage renal disease (ESRD) [2], which require kidney dialysis or a kidney transplant for the patient to live. erefore, the management of diabetes is becoming very important to avoid its serious metabolic outcomes such as nephropathy.
Nowadays, the treatment of diabetes involves diet control, exercise, the use of insulin and/or hypoglycemic drugs, and also the use of medicinal plants as complementary alternative medicine. Several medicinal plants have shown a crucial antihyperglycemic effect with minimal side effects [3][4][5], For this reason, the World Health Organization (WHO) has called a great attention to the rational use of traditional and natural medicines for treating diabetes [6].
T. hirsuta is a medicinal plant traditionally used for the prevention and the management of diabetes, in northeastern Morocco [8]. Previous pharmacological studies have demonstrated the acute antihyperglycemic effect of the Aq and Ea [11][12][13]. However, the medium-term antidiabetic effect of these two T. hirsuta extracts has not yet been established. erefore, the aim of the present study is to evaluate for the first time the medium-term antidiabetic activity of the Aq and Ea and to investigate their putative protective effect on pancreatic islet degeneration, diabetic nephropathy, liver steatosis, and aorta complications in STZ-induced diabetic rats.

Animals.
Wistar rats of both genders, initially weighing 150-250 g (8-9 weeks), were obtained from the animal house of the Department of Biology of the Faculty of Sciences (Oujda, Morocco). e study has been carried out along the "Principles of Laboratory Animal Care" [14]. ey were maintained under standard laboratory conditions (light/ dark cycle of 12/12 h and temperature of 23 + 2°C with 3 rats per cage with access to food and water. To collect urine and determine water and food intake, rats were maintained in metabolic cages.

Induction of Diabetes.
After a 14 h fasting, the rats were intraperitoneally injected with a single dose of STZ (50 mg/ kg bw), prepared in a fresh and cold sodium citrate buffer (0.1 M citric acid and 0.1 M trisoduim citrate dihydrate) at pH 4.5, to induce diabetes [15]. After 1 week, rats with fasting blood glucose range of 1.26-2 g/l were considered as type 2 diabetic and they were included in the study.

Preparation of Plant
Sample. T. hirsuta was purchased from a traditional market in Oujda (Oriental Morocco) and was authenticated by a botanist in the Department of Biology (Faculty of Sciences, Oujda, Morocco), and a voucher specimen (HUMPOM137) was deposit at the plant section of the Herbarium University Mohamed Premier of Oujda, Morocco (HUMPO).
T. hirsuta's aerial parts were first cleaned and washed with water and then dried at 40°C overnight in the oven. To prepare Aq , 140 g of T. hirsuta aerial parts was infused in 2 L of distillated water for 3 hours.
e Aq yield was 4.53%. e Ea was prepared as described in our previous study [13].

Experimental Design.
e rats were randomly divided into five groups (5 or 6 rats per group): normal control rats (administered only with distillated water), diabetic control rats (administered only with distillated water), diabetic rats treated with 10 mg/kg bw of acarbose (standard hypoglycemic drug), diabetic rats treated with 50 mg/kg of Ea , and diabetic rats treated with 200 mg/kg bw of Aq . Optimal doses were determined based on our previous studies [13] and from preliminary tests. All rats were treated once daily for 4 weeks. e body weight was recorded every day. e water and food intake and urine volume were monitored before and after treatment, and glycosuria was measured at the end of the treatment. Fasting blood glucose was examined before the treatment (week 0) and after 1, 2, 3, and 4 weeks of treatment. e inhibition of α-glucosidase, in vivo, was studied the day before rats were sacrificed. After the 4 weeks of treatment, all the animals were anesthetized by 50 mg/kg of pentobarbital, after 14 h of fasting. en, the blood was collected, by cardiac puncture, and immediately centrifuged at 3000 tour/min for 10 min. e serum was then stored at −20°C until biochemical analysis (total cholesterol and triglycerides). e kidney, liver, aorta, heart, and pancreas were removed, weighted (kidney liver and heart), and then fixed (kidney, liver, aorta, and pancreas) in 10% formalin for the histological study. A liver's sample was stored at −20°C for glycogen content's assay.

Estimation of Fasting Blood Glucose.
During the treatment period, the fasting glycemia was quantified weekly. After 14 h of fasting, blood was removed from the tail vein rats, under light ether anesthesia, using microcapillaries. en, it was centrifuged at 5000 ×g for 10 min, and glycemia was estimated in the serum using a commercially glucose kit (BioSystems, Spain) based on the glucose oxidase peroxidase method [16].

α-Glucosidase Inhibition, in vivo Study.
e day before the sacrifice, the rats deprived of food for 14 h were used to monitor the α-glucosidase inhibition, in vivo. 30 min prior oral sucrose load (2 g/kg), each group was administrated by the dose corresponding to its treatment. e blood was collected, from the tail vein using microcapillaries, just before the test dose administration (−30 min), immediately 2 e Scientific World Journal before sucrose load (0 min), and at 30, 60, and 120 min after sucrose load. After centrifugation at 5000 ×g/10 min, the plasma glucose level was determined by the glucose oxidase peroxidase method [17].

Extraction and Determination of Hepatic Glycogen.
Weighed samples of liver tissues (0.3-0.5 g) from all groups were used to extract glycogen according to Ong and Khoo [18]. Liver samples were first crushed, homogenized with 2 ml of 30% potassium hydroxide (KOH), and boiled at 100°C/30 min. en, for precipitating glycogen, the mixture was treated twice with 4 ml 95% ethanol, and each time, the mixture was stored at 4°C/30 min. After centrifugation at 3000 tours/min/15 min, the pellet was washed with 8 ml 95% ethanol and then centrifuged at 3000 tours/min/15 min. e glycogen obtained was solubilized in 1 ml distillated water. e glycogen concentration was monitored using anthrone reagent. e optic density was read at 625 nm.

Biochemical
Assays. Glycosuria was measured by a commercial Autokit (BioSystems, Spain) based on the glucose oxidase peroxidase method. Glycosylated hemoglobin (HbA1c) was estimated using a commercial kit (Cal-tech Diagnostics, INC, USA), and cholesterol was determined using commercial assay kits (SGM-Italia, Roma, Italy). Triglycerides and urinary creatinine were estimated using commercial assays kits (Bio Sud Diagnostici S.R.L, Ricerca, Italy).
en, for hematoxylin and eosin staining, after 20 min of washing, cell nuclei were stained with immersed in hematoxylin for 5 min, followed by 15 min of washing by water. To stain cytoplasm, the sections were immersed in 1% eosin for 5 min, then washed for 2 min. After coloration, sections were dehydrated with 100% ethanol (2 × 1/2 min) and toluene (2 × 2 min). For Masson's trichrome staining, after the hydratation, kidney and aorta sections were refixed in Bouin's solution for 1 hour/56°C. en, after 10 min washing, sections were stained in Weigert's iron hematoxylin for 2 min. After 10 min rinsing, sections were immersed in fuchsin acid for 3 min, and after 10 min washing, they were differentiated in phosphomolybdic acid for 15 min. To stain collagen, sections were transferred directly to light green for 15 min. After 2 min differentiation in 1% acetic acid, sections were dehydrated through 95% and 100% ethanol for 1 min each and then cleared in toluene (2 × 1 min) [19][20][21].
Finally, sections stained on lamellas were mounted in Permount. After drying, the microscopic observation was made using the 40x objective ocular system of Olympus Tokyo (Japan) light microscope.
To determine drug's effect on pancreas tissue, the pancreatic islet cell number and diameter were calculated. To quantify collagen on kidney sections, results were scored from zero to three (0: no collagen, 1: weak collagen, 2: moderate collagen, and 3: strong collagen) [22]. e treatment effect on aorta was evaluated by measuring the aorta diameter, and liver damage was elucidated by the development of lipid droplets.

Statistical Analysis.
All the values were expressed as mean ± SEM. e statistical analysis and comparison of means was performed using the unpaired Student test to compare two groups' means and paired Student test to compare two means inside the same group. To determine the protective drug effect on the kidneys and liver, the chisquare test was used. p values <0.05 were considered significant.

Effect of Drug Treatment on Fasting Blood Glucose in STZ-
Induced Diabetic Rats. In untreated diabetic control rats, a significant fasting blood glucose elevation was observed compared to normal control rats. Treatment with 200 mg/kg Aq decreased blood glucose level from the 1 st week of administration, and this effect was significant at the 3 rd (p < 0.001) and 4 th week (p < 0.05) compared to untreated diabetic rats. Treatment with 50 mg/kg Ea reduced hyperglycemia from the 2 nd week, and this effect was significant (p < 0.05) at the 3 rd and 4 th week. At 2 nd , 3 rd , and 4 th week, Ea effect was statistically similar to that of 10 mg/kg acarbose ( Figure 1).

Effect of Drugs on α-Glucosidase Activity, in vivo Study.
In normal control rats, blood glucose was increased to 1.48 g/l.30 min after sucrose loading and then it returns to normal value at 120 min whereas in untreated diabetic rats, glycemia was increased to 2.76 g/l at 30 min of sucrose loading to achieve 2.85 g/l at 120 min. 50 mg/kg Ea has significantly (p < 0.05) prevented the hyperglycemia induced by sucrose loading at 30 and 60 min compared with untreated diabetic rats. In the 200 mg/kg Aq group, no antihyperglycemic effect was shown. Blood glucose level reached 2.63 g/l and 2.70 g/l at 30 and 60 min, respectively, and it decreased to 2.21 g/l at 120 min. 10 mg/kg acarbose has significantly (p < 0.01) prevented the hyperglycemia induced by sucrose loading at 30, 60, and 120 min compared to diabetic control. e effect of acarbose was statistically similar to Ea effect ( Figure 2).

Effect of Drug Treatment on Body Weight, Food, and Water
Intake. e body weight gain by untreated diabetic rats was significantly (p < 0.05) decreased compared with normal rats. Aq has significantly (p < 0.05) prevented the body weight fall compared with untreated diabetic rats. Ea -and acarbose-treated rats did not significantly (p > 0.05) change the body weight gain compared to untreated diabetic rats. At the end of treatment, water intake did not change in untreated diabetic rats, Aq , Ea , and acarbose groups compared to the data before treatment whereas food intake was significantly increased in diabetic rats and Aq -, Ea -, and acarbose-treated rats (p < 0.05, p < 0.05, p < 0.05, and p < 0.01, respectively) compared to before drug administration (Table 1).

Effect of Drug Treatment on Urinary Parameters.
After the 4-week treatment period, urinary creatinine and glycosuria were significantly increased (p < 0.05 and p < 0.001, respectively) in untreated diabetic rats when compared to normal rats. Oral administration of Aq has decreased significantly (p < 0.05) urinary creatinine compared to untreated diabetic rats, but no significant difference has observed on glycosuria when compared with untreated diabetic rats. Ea treatment has prevented urinary creatinine increase compared to normal rats; however, Ea did not change significantly glycosuria. On the other hand, the Aq and Ea effect on urinary creatinine and glycosuria was statistically similar to that of 10 mg/kg acarbose. Finally, there was no significant difference on urinary volume when comparing data before and after treatment with Aq , Ea , or acarbose (Table 2).

Effect of Drug Treatment on Biochemical Parameters.
After the 4-week treatment period, HbA1c was significantly increased (p < 0.05), in untreated diabetic rats when compared to normal rats. Oral administration of Aq has prevented HbA1c elevation compared to normal rats. At the end of the treatment period, liver glycogen quantity was significantly decreased (p < 0.05) in untreated diabetic rats when compared to normal rats. Aq and Ea treatments have shown no significant effect on liver glycogen compared to untreated diabetic rats whereas acarbose treatment did not change liver glycogen quantity compared to normal rats. Finally, total cholesterol and triglycerides results show that there is no significant change after Aq , Ea , or acarbose treatment compared to normal and diabetic rats (Table 3).    Table 4 shows liver, kidney, and heart weight at the end of the treatment period. Results indicate that kidney weight was significantly increased in untreated diabetic rats as compared to normal rats. Treatment with 200 mg/kg Aq or 50 mg/kg Ea did not change liver, kidney, and heart weight when compared to untreated diabetic rats whereas there is a significant elevation in liver and heart weight of acarbose-treated rats compared to untreated diabetic rats.

Pancreas Changes.
Light microscopic observation of pancreatic islet cells from normal rats shows normal histological appearance with large diameter and high granulation density (Figure 3). In untreated diabetic rats, a significant reduction of diameter and islet cell number (p < 0.001 and p < 0.01, respectively) was observed. Treatments with 200 mg/kg Aq have significantly prevented the reduction of diameter and cell number of Langerhans islet (p < 0.01 and p < 0.05, respectively). As the same, 50 mg/kg Ea has significantly (p < 0.05) protected diameter and cell number against reduction. Treatment with 10 mg/kg acarbose has prevented significantly (p < 0.05) the reduction of the islet cell number.

Kidney Changes.
e Masson staining marks in blue/ green collagen fibers, in brown nuclei, in red muscle fiber cytoplasm, and in orange blood cells. Minimal tubulointerstitial collagen was observed in the normal group ( Figure 4). A significant increase (p < 0.01) of tubulointerstitial collagen was detected in untreated diabetic rats. Treatment with 200 mg/kg Aq and 50 mg/kg Ea has prevented significantly (p < 0.001 and p < 0.05, respectively) the tubulointerstitial collagen compared to untreated diabetic rats, but 10 mg/kg acarbose treatment did not change significantly (p > 0.05) this tubulointerstitial collagen. On the other hand, glomeruli collagen was observed in 33.3% of normal rats. In diabetic rats, glomeruli collagen was detected in all rats (100%). Treatment with 200 mg/kg Aq has significantly reduced (p < 0.05) glomeruli collagen to 40%, but Ea and acarbose did not (Figure 4). Each value is mean ± SEM. n � 5-6 rats. Aq : aqueous extract; Ea : ethyl acetate fraction. # p < 0.05 compared with the normal group. $ p < 0.05 compared with the diabetic group. * p < 0.05 and * * p < 0.01 compared with before treatment in the same group. All statistical tests were used with one-tail p value. Each value is mean ± SEM. n � 5-6 rats. Aq : aqueous extract; Ea : ethyl acetate fraction. I p > 0.05 compared with before treatment in the same group. * p < 0.05 and * * * p < 0.001 compared with the normal group. # p < 0.05 compared with the diabetic group. All statistical tests were used with one-tail p value.  Sections were stained in hematoxylin and eosin and observed in light microscope (original magnification ×400). * * p < 0.01 and * * * p < 0.001 compared to normal rats; $ p > 0.05, # p < 0.05, and ## p < 0.01 compared to diabetic rats. Each value represents the means ± SEM. n � 5-6.  (c) Glomeruli collagen for all groups. Sections were stained in Masson's trichrome and observed in light microscope (original magnification ×400). White arrow: collagen. Each value represents the means ± SEM. n � 5-6. x/x: number of rats with glomeruli collagen in the group. * p < 0.05 and * * p < 0.01 compared to normal rats. ns p > 0.05 compared to diabetic rats; # p < 0.05 and ### p < 0.001 compared to diabetic rats. All statistical tests were used with one-tail p value. e Scientific World Journal

Liver Changes.
Examination of hematoxylin and eosin stained sections showed that normal rats had a normal histological appearance. In untreated diabetic rats, an important degenerative change in the liver tissue was observed. Lipid droplets were appeared in all the rats (100%). Treatment with 200 mg/kg Aq and 50 mg/kg Ea has significantly (p < 0.05) attenuated this effect. e percentage of protection was 60 and 50%, respectively. However, 10 mg/kg acarbose treatment did not attenuate this liver damage ( Figure 5).

Aorta
Changes. Light microscopic observation shows that untreated diabetic rats had normal aorta diameter compared to normal rats. Treatment with 200 mg/kg Aq , 50 mg/kg Ea , or 10 mg/kg acarbose did not significantly change aorta diameter compared to normal and diabetic rats ( Figure 6).

Discussion
In this study, we demonstrated for the first time the antidiabetic effect of T. hirsuta medium-term administration (4 weeks) and its prevention of renal and liver complications in STZ-induced diabetic rats.
Our results indicated that the medium-term treatment with 200 mg/kg Aq or 50 mg/kg Ea decreases significantly fasting blood glucose in STZ-treated diabetic rats comparing with STZ-untreated diabetic rats. Ea has shown a similar α-glucosidase inhibitory activity when compared to 10 mg/kg acarbose, but Aq has not inhibited α-glucosidase activity after sucrose loading. ese results indicate that the medium-term antihyperglycemic effect of Ea is related to intestinal α-glucosidase inhibition. So, this finding confirms our previous results [13] whereas the antidiabetic effect of Aq seems to be related to another mechanism than the α-glucosidase pathway. In addition, we have observed a reduction on HbAc1 level in Aq -treated diabetic rats while Ea treatment did not change HbAc1 level when compared to untreated diabetic rats. is explains why α-glucosidase inhibitors are often prescribed with other antidiabetic drugs in diabetic treatment.
Histopathological study of the sections of pancreas showed that the administration of Aq and Ea for 4 weeks significantly increases diameter and cell number in Langerhans islets. Similar studies had proved that many plant extracts significantly restored the diameter of islets and the number of β cells in diabetic rats [23][24][25].
Consequently, the plausible mechanism of action of Aq in controlling the blood glucose level might be the enhancement of secretion of insulin from pancreatic β-cells. As other possible mechanisms, the Aq may sensitize the insulin receptor to insulin or stimulate the stem cells of the islets of Langerhans in the pancreas of STZ-induced diabetic rats [25]. erefore, we conclude that the antihyperglycemic phytochemical compounds present in Aq are different to those of Ea .
Many studies proved that the secondary metabolites such as flavonoids, tannins, and terpenoids have potential inhibitory effects on alpha glucosidase [26][27][28]. In a previous study of our team, a polyphenol-rich fraction of T. hirsuta has demonstrated a potent antidiabetic effect in diabetic rats [29]. us, the α-glucosidase inhibitory action of Ea is due probably to the presence of flavonoids.
It is well known that diabetes is associated with macrovascular and microvascular complications such as nephropathy. Statistics showed that of all dialysis patients, diabetics represent 20.6% in 2001 against 13.1% in 1995 and 6.9% in 1989. e mortality rate of patients on dialysis is significantly higher in diabetics than in nondiabetes (241.4/ 1000 vs. 153.99/1000 person-years) [30]. e average survival of type 2 diabetes entering dialysis is approximately 3 years [31,32]. Diabetic nephropathy is characterized by the accumulation of some proteins such as collagen in the glomerular mesangium and in the tubulointerstitial space that lead to renal fibrosis and so to renal failure [33][34][35]. In this study, we have demonstrated that medium-term oral administration of 200 mg/kg Aq or 50 mg/kg Ea prevents urinary creatinine increasing and tubulointerstitial renal collagen when compared to untreated diabetic rats as shown in kidney histopathological results.
ese finding demonstrate that Aq and Ea could protect against renal fibrosis through the inhibition of the extracellular matrix (ECM) protein accumulation.
ese results are similar to other ethnopharmacological studies which demonstrated that garlic and Sclerocarya birrea ameliorate the process of renal fibrosis in diabetic nephropathy [36,37]. e protective effect against renal ECM protein accumulation is due to the inhibition of the protein kinase B/mammalian target of the rapamycin (PKB/mTOR) signaling pathway [38]. Recent research studies had demonstrated that the activation of PKB causes the activation of mTORC1 and its downstream protein p70S6K, which are critical regulators of cell growth, cell proliferation, and protein synthesis [39,40].
Consequently, the management of diabetes mellitus with Aq and Ea compounds could have helpful effects on renal function in diabetic patients.
Evidence suggests that in diabetic rats, a complex alteration in the activities of antioxidant enzymes was observed [41]. is alteration leads to tissue damage and plays an important role in the pathogenesis of diabetic complications. In the present study, liver histopathological results show that untreated diabetic rats develop liver steatosis characterized by lipid droplets. Other studies found that the liver was necrotized in STZ-induced diabetic rats [42]. STZ is considered a classic model of diabetes induction because it provokes toxicity to pancreatic β-cells and cellular death [43], resulting in hypoinsulinemia and hyperglycemia. Insulin plays important metabolic role as a suppressor of lipolysis in adipose tissue [44].
us, hypoinsulinemia in diabetes leads to an increased release of free fatty acids (FFAs) in the bloodstream [45] and influx of acids to the liver. Intrahepatic triglyceride accumulation occurs when the influx of lipids to the liver surpasses the hepatic capacity to export triglycerides to the bloodstream   (1), diabetic (2), Aq -treated (3), Ea -treated (4), and acarbose-treated rats (5). (b) Percentage of rats with liver lipid droplets. Sections were stained in hematoxylin and eosin and observed in light microscope (original magnification ×400). White arrow: lipid droplets. Each value represents the means ± SEM. n � 4-6. x/x: number of rats with lipid droplets in the group. * p < 0.05 and * * p < 0.01 compared to normal rats. ns p > 0.05 compared to normal rats. All statistical tests were used with one-tail p value. e Scientific World Journal 10 e Scientific World Journal [45] which causes the development of hepatic steatosis as diabetic complication [46]. In the present study, the histopathological data show that the medium-term oral administration of 200 mg/kg Aq or 50 mg/kg Ea protects significantly the liver under the steatosis via decreasing lipid droplet accumulation. Similar findings were reported by Eliza et al. [47] where Costus speciosus decreased hepatic disorder. In addition, other studies showed that Camellia oleifera seed ameliorates hepatic steatosis via the regulation of FFA [48] and curcumin reduces steatohepatitis and lipid deposition through being an antioxidant and exerting anti-inflammatory and free radical scavenger roles [49]. However, acarbose treatment did not have this liver protective propriety. is confirms the side effect of this drug in the liver [50].
Furthermore, T. hirsuta contains sterols, coumarins, terpenes, tannins, aliphatic alcohol, lactone, alkanes, and alkanols [51]. Interestingly, Aq and Ea antihyperglycemic and antidiabetic effects might be due to the presence of these phytochemicals or other unknown compounds.

Conclusions
In conclusion, our study has shown that the mediumterm administration of Aq and Ea of T. hirsuta had the potential to decrease blood glucose in STZ-induced diabetic rats. e antihyperglycemic effect of Ea may be partially explained by the inhibition of intestinal α-glucosidase activity. And the Aq antihyperglycemic activity can be attributed to the stimulation of insulin secretion from pancreatic islet cells. In addition, Aq and Ea have shown a crucial preventive effect against renal fibrosis and liver steatosis complications.
us, these findings suggest that Aq and Ea could be considered as an efficient oral antidiabetic treatment. Currently, our studies are focused on the isolation and identification of the active compounds of Ea and Aq , which are responsible for the antidiabetic effect of T. hirsuta.

Data Availability
e data used to support the findings of this study are available on request from the authors.

Conflicts of Interest
e authors declare that there are no conflicts of interest.